SCI
RARE icon

S&CO Inc’s Ultragenyx Pharmaceutical RARE Stock Holding History

S&CO Inc’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$529K Hold
25,255
– – 0.03% 165
2025
Q4 		$580K Hold
25,255
– – 0.04% 167
2025
Q3 		$759K Hold
25,255
– – 0.05% 161
2025
Q2 		$918K Buy
25,255
+5,000
+25% +$180K 0.06% 146
2025
Q1 		$733K Hold
20,255
– – 0.05% 159
2024
Q4 		$852K Hold
20,255
– – 0.06% 144
2024
Q3 		$1.13M Hold
20,255
– – 0.07% 135
2024
Q2 		$832K Buy
+20,255
New +$865K 0.06% 149

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

S&CO Inc's RARE Position: Q1 2026 in Review

S&CO Inc held its Ultragenyx Pharmaceutical (RARE) position steady in Q1 2026 at 25,255 shares worth $529K. The position accounts for 0.03% of the portfolio, ranked #165.

S&CO Inc first reported a position in RARE in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.13M in Q3 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • S&CO Inc held 25,255 shares of Ultragenyx Pharmaceutical worth $529K as of Q1 2026.
  • S&CO Inc left its Ultragenyx Pharmaceutical share count unchanged in Q1 2026.
  • Ultragenyx Pharmaceutical made up 0.03% of S&CO Inc's portfolio in Q1 2026, its #165 holding.
  • S&CO Inc first reported a position in Ultragenyx Pharmaceutical in Q2 2024 and has held it in 8 quarters since.
  • S&CO Inc's Ultragenyx Pharmaceutical position peaked at $1.13M in Q3 2024.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on S&CO Inc's 13F filing for Q1 2026, filed 7 May 2026.